Coupang is entrenched in a severe, sustained downtrend, with the stock down 57.68% over the trailing twelve months and 41.04% year-to-date, a decline that has wiped out more than half of shareholder value. At a current price of $13.78, the stock sits at just 2.2% above its 52-week low of $13.35 and a staggering 58.2% below its 52-week high of $32.957, placing it in the bottom 2% of its annual range — a positioning that signals persistent selling pressure and momentum-driven capitulation rather than a value floor. The maximum drawdown of -58.99% confirms this is a deeply damaged chart, and while such extreme weakness can attract contrarian buyers, the absence of any stabilization pattern suggests the stock remains a falling knife until proven otherwise. Recent momentum offers no reprieve: the 1-month change of -13.71% and 3-month change of -25.75% show that the decline is accelerating rather than decelerating, with the pace of losses intensifying over the near term. This short-term weakness is consistent with — not divergent from — the longer-term trend, meaning there is no bullish divergence to suggest an imminent reversal. Relative strength metrics underscore the severity of underperformance: the stock trails SPY by 14.30 percentage points over 1 month, 29.09 points over 3 months, and a remarkable 72.69 points over 1 year, indicating that capital is actively fleeing this name in favor of market leaders. With a short ratio of 5.02, bears have built a meaningful position, and any positive catalyst could trigger a sharp squeeze, but the current momentum regime remains decisively negative. Key technical levels are starkly defined: the 52-week low at $13.35 represents the critical support zone, and a breakdown below it would likely open the door to new all-time lows and potentially trigger further systematic selling. To the upside, the stock faces layered resistance, with the 52-week high at $32.957 serving as the ultimate ceiling, though intermediate resistance would likely emerge around the $16-$18 zone where prior consolidation occurred. With a beta of 1.152, Coupang is approximately 15% more volatile than the broader market, meaning position sizing should account for amplified drawdowns relative to SPY — a factor that is particularly relevant given the stock's current freefall and the elevated uncertainty around its fundamental trajectory.

Coupang's revenue trajectory has decelerated sharply, with Q2 2026 revenue of $8.856 billion growing just 3.89% year-over-year — a dramatic slowdown from the double-digit growth rates the company historically commanded. Sequentially, revenue was essentially flat, rising from $8.504 billion in Q1 2026 to $8.856 billion in Q2, and actually declined from $9.267 billion in Q3 2025, indicating that the top line has stalled. Segment data reveals that the core Product business generated $6.744 billion, while Third-Party Merchant Services contributed $1.832 billion and Service/Other added $280 million, but the lack of segment-level growth rates makes it difficult to pinpoint whether the marketplace or the owned-inventory business is the primary drag. The broader implication is that Coupang's growth engine has lost significant momentum, and without a reacceleration, the company's premium valuation will be increasingly difficult to justify. Profitability has deteriorated dramatically, with Q2 2026 net income of -$570 million representing a net margin of -6.44%, a sharp reversal from the $32 million profit reported in Q2 2025. Gross margin compressed to 28.16% in Q2 2026 from 30.04% a year earlier, and operating income swung to -$556 million (a -6.28% operating margin) from +$149 million in the prior-year period. The EBITDA loss of $363 million in Q2 2026, versus positive EBITDA of $345 million in Q2 2025, underscores the magnitude of the profitability collapse, which appears driven by a combination of margin compression, rising operating expenses (SG&A of $3.05 billion), and likely investments in Farfetch and Taiwan. This is a concerning trajectory for a company that had been demonstrating a credible path to sustained profitability, and the market is now questioning whether the prior margin gains were structural or cyclical. The balance sheet and cash flow picture is mixed but increasingly strained: debt-to-equity stands at 1.003, the current ratio is a thin 1.036, and free cash flow TTM is just $107.5 million — a razor-thin cushion relative to the company's $42.9 billion market cap and capital-intensive operations. Q2 2026 operating cash flow was $367 million, but capital expenditures of $317 million consumed most of that, leaving free cash flow of only $50 million, while the company also repurchased $459 million in stock and repaid $325 million in debt. With ROE of just 4.50% and ROA of -2.14%, returns on capital are weak, and the company's ability to fund its growth initiatives internally is increasingly in question, raising the risk of external financing or further balance sheet deterioration if losses persist.